Tags : Chronic Myeloid Leukemia

Novartis Reports Results of Asciminib (ABL001) in P-III ASCEMBL Study

Shots: The P-III ASCEMBL study involves assessing of Asciminib (ABL001) vs bosutinib in patients with Ph+ CML-CP, prior treated with two or more TKIs The study met its 1EPs of superiority in major molecular response (MMR) rate @24wks. Asciminib (ABL001) is an investigational treatment specifically targeting the ABL myristoyl pocket (STAMP), being evaluated in multiple […]Read More

Takeda to Present Results of Iclusig (ponatinib) in P-II OPTIC

Shots: The P-II OPTIC study involves assessing three initial doses of Iclusig (15/30/45 mg) in 283 patients with CML in CF, or who had documented history of the presence of the T315I mutation after receiving any number of previous TKIs With an average follow-up of~ 21 mos., the interim analysis showed that maximum BCR- ABL1 […]Read More